文献速递妇科

细胞学阴性、非肌层浸润的IC期浆液性子宫内膜癌:辅助化疗省略的评估

Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission.
PubMed 文献 · Gynecol Oncol · 2025-06-09

本研究为回顾性队列研究,纳入国家癌症数据库2010至2015年间接受子宫切除和淋巴结评估的细胞学阴性、非肌层浸润IC期浆液性子宫内膜癌患者。结果显示,省略辅助化疗与总生存下降相关(10年总生存率68.0%对79.0%,HR 1.54)。

要点

  • 在细胞学阴性、非肌层浸润IC期浆液性子宫内膜癌中,省略辅助化疗与总生存下降相关(HR 1.54)。
  • 省略辅助化疗组10年总生存率为68.0%,接受辅助化疗组为79.0%。
  • 在细胞学阴性、内半肌层浸润IIC期队列中,省略辅助化疗同样与总生存下降相关(HR 1.60)。

核心结论

  • 在细胞学阴性、非肌层浸润IC期浆液性子宫内膜癌患者中,省略辅助化疗与总生存下降相关。

研究设计与样本

  • 回顾性队列研究,查询美国癌症委员会国家癌症数据库。
  • 研究人群为2010至2015年间接受初次子宫切除和淋巴结评估的非肌层浸润IC期浆液性子宫内膜癌患者,所有患者腹膜细胞学阴性(n=976)。
  • 采用逆概率治疗加权队列评估总生存。
  • 以细胞学阴性、内半肌层浸润IIC期作为概念验证队列(n=994)。

主要发现

  • 在非肌层浸润IC期队列(n=976)中,525例(53.8%)未接受辅助化疗。
  • 省略辅助化疗组10年总生存率为68.0%,接受辅助化疗组为79.0%,省略组较接受组低11.0%。
  • 省略辅助化疗 compared to 接受辅助化疗的全因死亡风险比为1.54(95%CI 1.22至1.96)。
  • 在内半肌层浸润IIC期队列(n=994)中,359例(36.1%)未接受辅助化疗。
  • 省略辅助化疗组10年总生存率为58.0%,接受辅助化疗组为68.7%,风险比为1.60(95%CI 1.30至1.96)。

关键数值与推荐

  • 美国国家综合癌症网络临床实践指南建议:对于非肌层浸润IC期浆液性子宫内膜癌,如果盆腔细胞学检查未显示恶性细胞,可考虑省略辅助化疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The National Comprehensive Cancer Network clinical practice guidelines suggest possible adjuvant chemotherapy omission for non-myoinvasive stage IC serous endometrial cancers if pelvic cytologic testing shows no malignant cells. Given the limited available data to support this recommendation, this study examined the association between adjuvant chemotherapy omission and survival in patients with cytology-negative, non-myoinvasive stage IC serous endometrial cancers. METHODS: This retrospective cohort study queried the Commission-on-Cancer's National Cancer Database. The study population included patients with non-myoinvasive stage IC serous endometrial cancer who had primary hysterectomy and nodal evaluation from 2010 to 2015. All patients had negative peritoneal cytology. Inverse probability of treatment weighting cohort was created to assess overall survival. Cytology-negative, inner-half myoinvasive stage IIC was evaluated as the proof-of-concept cohort. RESULTS: In the non-myoinvasive stage IC cohort (n=976), 525 (53.8%) patients did not receive adjuvant chemotherapy. The 10-year overall survival rate for the adjuvant chemotherapy omission group was 11.0% lower compared to the adjuvant chemotherapy treatment group (68.0% versus 79.0%). Hazard risk for all-cause mortality of adjuvant chemotherapy omission compared to adjuvant chemotherapy treatment was 1.54 (95% confidence interval 1.22 to 1.96). In the inner-half myoinvasive stage IIC cohort (n=994), 359 (36.1%) patients did not receive adjuvant chemotherapy. Overall survival for the adjuvant chemotherapy omission group was poorer compared to the adjuvant chemotherapy treatment group (10-year rate 58.0% versus 68.7%, hazard ratio 1.60, 95% confidence interval 1.30 to 1.96). CONCLUSION: In this cohort study, adjuvant chemotherapy omission was associated with decreased overall survival for patients with cytology-negative, non-myoinvasive stage IC serous endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Friedman EL, Lee MW, et al. Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission. Gynecol Oncol. 2025. PMID: 40494090. doi:10.1016/j.ygyno.2025.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。